Pharma Supply Chain Security

The ineffective management of supply chains by manufacturers and distributors has allowed counterfeiters and smugglers to evolve rapidly and become very creative and excel in producing counterfeit medicines and inserting them into the legitimate supply chains, meaning that many fake medicines go undetected. To counter this issue, global organizations, such as the World Health Organization (WHO), the European Union (EU), and the US Food and Drug Administration (FDA), work together to protect the safety and security of patients through pharma supply chain security.

Evolution in Supply Chain Management

DSCSA (Drug Supply Chain Security Act) established a 10-year roadmap with enforcement and adaptations in 2015 and 2018 related to Product Tracing, Product identifiers, Authorized Trading Partners, and Verification. The last section of the law, is Electronic Drug Distribution Security (EDDS). Among other things, EDDS directs all trading partners to have in place a secure, electronic, and interoperable system for the exchange of transaction documentation [transaction information (TI) and transaction statements (TS)] to enable the tracing of prescription medications.

Features:

• Graphs, charts, tables and visualizations complement the analysis
• Forecasts, projections of future market activity are derived using standard modeling and statistical techniques.

What You Will Learn:

• Provides detailed analysis DSCSA strategies, and workflow component factors.
• Assesses key stakeholders, market dynamics and market demographics.
• Analyzes therapeutic demand drivers and evaluates readiness in key supply chain segments.
• Provides market data and forecasts.
• Profiles market sector participants, their market activities, business strategies, and corporate alliances and affiliations
• Assesses the importance of alliances and partnerships on DSCSA implementation.
• Evaluates the impact of supply chain security economic, technology, and regulatory factors.